Excitation-light blocking filter for photoimmunotherapy tailored to the ORBEYE 4K 3D exoscope.

IF 3 3区医学 Q3 ONCOLOGY

International Journal of Clinical Oncology Pub Date : 2026-10-01 Epub Date: 2026-07-22 DOI:10.1007/s10147-026-03131-x

Ryuhei Okada, Hideki Kanebako, Ryosuke Takahashi, Taisei Nagahisa, Shigeru Kondo, Takaaki Sato, Tomoaki Asamori, Kazuchika Ohno, Michiko Machida, Takahiro Asakage

{"title":"Excitation-light blocking filter for photoimmunotherapy tailored to the ORBEYE 4K 3D exoscope.","authors":"Ryuhei Okada, Hideki Kanebako, Ryosuke Takahashi, Taisei Nagahisa, Shigeru Kondo, Takaaki Sato, Tomoaki Asamori, Kazuchika Ohno, Michiko Machida, Takahiro Asakage","doi":"10.1007/s10147-026-03131-x","DOIUrl":null,"url":null,"abstract":"Background: Photoimmunotherapy, which involves combining targeted antibodies with light-activatable dyes such as IRDye700DX (IR700), is an emerging cancer treatment modality. Cetuximab-based photoimmunotherapy is approved for the treatment of unresectable head and neck cancer and has been covered by the national health insurance in Japan since 2021. Use of conventional ceiling surgical lighting during photoimmunotherapy is problematic due to concerns about potential cytotoxic effects.Methods: To ensure safe surgical application, we developed a custom short-pass filter for the ORBEYE surgical exoscope to block IR700 excitation light. The filter's impact on the color tone was evaluated using human skin and a color checker, while that on the cytotoxicity was assessed in vitro using cetuximab-IR700 and an HSC-3 cell line. The clinical feasibility of using this filter was tested in six patients who underwent short surgical procedures (e.g., tracheostomy, arterial ligation) during photoimmunotherapy.Results: Recalibrating the white balance after filter placement preserved the natural color tones. In vitro, the filter neutralized the significant cytotoxicity observed under the ORBEYE light. Clinically, the filter could be used safely in all cases with no evidence of postoperative skin damage.Conclusion: This filter system enhances the safety and feasibility of surgical procedures during photoimmunotherapy.","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2243-2248"},"PeriodicalIF":3.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615148/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-026-03131-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Photoimmunotherapy, which involves combining targeted antibodies with light-activatable dyes such as IRDye700DX (IR700), is an emerging cancer treatment modality. Cetuximab-based photoimmunotherapy is approved for the treatment of unresectable head and neck cancer and has been covered by the national health insurance in Japan since 2021. Use of conventional ceiling surgical lighting during photoimmunotherapy is problematic due to concerns about potential cytotoxic effects.

Methods: To ensure safe surgical application, we developed a custom short-pass filter for the ORBEYE surgical exoscope to block IR700 excitation light. The filter's impact on the color tone was evaluated using human skin and a color checker, while that on the cytotoxicity was assessed in vitro using cetuximab-IR700 and an HSC-3 cell line. The clinical feasibility of using this filter was tested in six patients who underwent short surgical procedures (e.g., tracheostomy, arterial ligation) during photoimmunotherapy.

Results: Recalibrating the white balance after filter placement preserved the natural color tones. In vitro, the filter neutralized the significant cytotoxicity observed under the ORBEYE light. Clinically, the filter could be used safely in all cases with no evidence of postoperative skin damage.

Conclusion: This filter system enhances the safety and feasibility of surgical procedures during photoimmunotherapy.

查看原文本刊更多论文

专为ORBEYE 4K 3D外窥镜定制的光免疫治疗的兴奋光阻挡滤光片。

背景：光免疫疗法是一种新兴的癌症治疗方式，它将靶向抗体与IRDye700DX （IR700）等光活化染料结合使用。基于西妥昔单抗的光免疫疗法被批准用于治疗不可切除的头颈癌，自2021年以来已被纳入日本的国民健康保险。由于担心潜在的细胞毒性作用，在光免疫治疗期间使用传统的天花板手术照明是有问题的。方法：为了确保手术应用安全，我们为ORBEYE手术外窥镜开发了一种定制的短通滤光片来阻挡IR700激发光。使用人体皮肤和颜色检测器评估滤镜对色调的影响，而使用西妥昔单抗- ir700和HSC-3细胞系评估滤镜对细胞毒性的影响。在光免疫治疗期间接受短时间手术（如气管切开术、动脉结扎）的6例患者中测试了使用该过滤器的临床可行性。结果：滤镜放置后重新校准白平衡，保留了自然色调。在体外，滤光片中和了ORBEYE光下观察到的显著细胞毒性。临床证明，该滤器在所有病例中均可安全使用，无术后皮肤损伤迹象。结论：该过滤系统提高了光免疫治疗手术过程的安全性和可行性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Oncology 医学-肿瘤学

CiteScore

6.80

自引率

3.00%

发文量

175

审稿时长

2 months

期刊介绍： The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.